ObsEva receives Investment Bank Analyst Rating Update
Pre-Open Stock Movers: ObsEva SA (NASDAQ:OBSV) 74% LOWER; plans to initiate a corporate restructuring and refocus the Companys development and commercialization strategy. ObsEva...
ObsEva SA (NASDAQ:OBSV) reported Q1 EPS of ($0.14), $0.06 better than the analyst estimate of ($0.20).
1. Adverum Biotechnologies (ADVM) ADVM made a powerful move on Tuesday, above a double-top and breakaway gap, and jumped 5.27, or 38%, to 19.00, after reaching a multi-week and...
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) announced that it has entered into a partnership with Duchenne UK, a charity to fund its phase II study on the lead pipeline...
Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis (phase 2b of clinical trials) and uterine fibroids (phase 3 of clinical trials); Nolasiban (OBE001), an oral oxytocin receptor antagonist undergoing phase 3 of clinical trials, with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART), and OBE022, an oral and selective prostaglandin F2 alpha (PGF2a) receptor antagonist designed to control preterm labor (phase 2a of clinical trials).